Related Experiment Video
Updated: Jul 14, 2026
12:03
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Interfering with disease: a progress report on siRNA-based therapeutics.
Antonin de Fougerolles1, Hans-Peter Vornlocher, John Maraganore
1Alnylam Pharmaceuticals Inc., 300 Third Street, Cambridge, Massachusetts 02142, USA. tdefougerolles@alnylam.com
Nature Reviews. Drug Discovery
|June 2, 2007
Summary
RNA interference (RNAi) offers a novel therapeutic strategy by silencing disease-related genes. This review covers RNAi drug development from initial design to clinical trials.
Area of Science:
- Molecular Biology
- Pharmacology
- Genetics
Background:
- RNA interference (RNAi) is a natural gene-silencing mechanism discovered in the 1990s.
- RNAi was demonstrated in mammalian cells in 2001, highlighting its therapeutic potential.
- Sequence-specific gene silencing offers a novel approach to targeting disease-associated genes.
Purpose of the Study:
- To discuss the development of RNA interference-based therapeutics.
- To outline key considerations from in vitro drug design to in vivo preclinical testing.
- To review current clinical progress in RNAi therapeutics.
Main Methods:
- In vitro lead identification and optimization.
- Preclinical in vivo drug delivery strategies.
- Clinical trial data analysis for RNAi therapeutics.
Main Results:
- RNAi therapeutics leverage sequence-specific gene silencing for therapeutic benefit.
- Successful preclinical development requires careful consideration of in vitro and in vivo factors.
- Emerging clinical data demonstrate the viability of RNAi-based treatments.
Conclusions:
- RNAi therapeutics represent a promising new class of drugs.
- The development pathway involves rigorous in vitro and in vivo validation.
- Clinical advancements indicate a growing role for RNAi in medicine.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
02:30Small interfering RNAs (siRNA)
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...